Summary
The old saying ‘red as a beet, dry as a bone, blind as a bat, hot as a hare, mad as a hatter’ is often quoted when describing the autonomic effects of drugs that block the muscarinic cholinergic system. These effects may be subtle or dramatic, yet can be overlooked or discounted as a natural consequence of old age. Elderly patients can be particularly sensitive to the anticholinergic action of drugs because of physiological and pathophysiological changes that often accompany the aging process. The use of multiple drugs, a common finding in older patients, may result in pharmacodynamic and pharmacokinetic drug interactions that heighten anticholinergic effects. While the classic anticholinergic problems of decreased secretions, slowed gastrointestinal motility, blurred vision, increased heart rate, heat intolerance, sedation and possibly mild confusion, may be uncomfortable for a younger patient in relatively good health, these effects can be disastrous for older patients.
Even the most common peripheral anticholinergic complaint of dry mouth can reduce the ability to communicate, predispose to malnutrition, promote mucosal damage, denture misfit or dental caries, and increase the risk of serious respiratory infection secondary to loss of antimicrobial activity of saliva. Mydriasis and the inability to accommodate will impair near vision and may precipitate narrow angle glaucoma in predisposed patients, but less obviously could lead to an increased risk of accidents, including falls. Somatic complaints of constipation and urinary hesitancy, could, in the presence of anticholinergic challenge, result in faecal impaction or urinary retention. Cardiac effects may be poorly tolerated. Increases in heart rate may precipitate or worsen angina. Finally, thermoregulatory impairment induced by anticholinergics, which block the ability to sweat, may lead to life threatening hyperthermia.
Central anticholinergic effects range from sedation, mild confusion and inability to concentration to frank delirium. Even mild effects can reduce function and increase dependency. At any level of care, the loss of independence increases the caregiver burden, costs, and most importantly, can negatively affect quality of life.
Many age-related and disease-related conditions may predispose elderly patients to anticholinergic drug toxicity. Careful attention to anticholinergic effects when prescribing drugs, patient education, regular review of the entire drug regimen, and familiarity with the signs and symptoms of anticholinergic toxicity will help to reduce the risk of drug-induced problems.
Similar content being viewed by others
References
Allen MD, Greenblatt DJ, Noel BJ. Self-poisoning with over-the-counter hypnotics. Clinical Toxicology 15: 151–158, 1979
Anonymous. Terodiline withdrawn worldwide. Scrip No 1653: 19, 20 Sep, 1991
Anonymous. Antipsychotic agents. In Drug facts and comparisons, pp. 265–268a, Facts and Comparisons, St Louis, 1993
Baigrie RJ, Kelleher JP, Fawcett DP, Pengelly AW. Oxybutynin: is it safe? British Journal of Urology 62: 319–322, 1988
Bailie GR, Parker WA. Iatrogenic anticholinergic intoxication syndrome. Canadian Journal of Hospital Pharmacy 37: 98–101, 1984
Barker DB, Solomon DA. The potential for mental status changes associated with systemic absorption of anticholinergic ophthalmic medications: concerns in the elderly. DICP: Annals of Pharmacotherapy 24: 847–850, 1990
Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408–417, 1982
Beers MH, Ouslander JG. Risk factors in geriatric drug prescribing: a practical guide to avoiding problems. Drugs 37: 105–112, 1989
Bigger JT, Hoffman BF. Antiarrhythmic drugs. In Gilman et al. (Eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 8th ed., pp. 848–857, Pergamon Press, Elmsford, 1990
Blazer DG, Federspiel CF, Ray WA, Schaffner W. The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. Journal of Gerontology 38: 31–35, 1983
Branconnier RJ, Cole JO. Effects of acute administration of trazodone and amitriptyline on cognition, cardiovascular function, and salivation in the normal geriatric subject. Journal of Clinical Psychopharmacology 1 (Suppl. 6): 82S–88S, 1981
Branconnier RJ, Devitt DR, Cole JO, Spera KF. Amitriptyline selectively disrupts verbal recall from secondary memory of the normal aged. Neurobiology of Aging 3: 55–59, 1982
Brown JH. Atropine, scopolamine, and related antimuscarinic drugs. In Gilman et al. (Eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 8th ed., pp. 150–165, Pergamon Press, Elmsford, 1990
Buckley P, Larkin C, O’Callaghan E. Psychosis following use of proprietary antidiarrhoeal medicines. British Journal of Psychiatry 157: 758–759, 1990
Burnett GB, Prange AJ, Wilson IC, Jolliff LA, Creese IC, et al. Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. Neuropsychobiology 6: 109–120, 1980
Creasey H, Rapoport SI. The aging human brain. Annals of Neurology 17: 2–10, 1985
Danziger LH, Horn JR. Disopyramide-induced urinary retention. Report of nine cases and review of the literature. Archives of Internal Medicine 143: 1683–1686, 1983
Department of Health and Human Services. Health care financing administration. Medicare and Medicaid: requirements for long term care facilities final regulations, 42 CFR Parts 442 et al, September 26, 1991. Document No. 869-017-00159-7, Government Printing Office, Washington, D.C.
Department of Health and Human Services. Health Care Financing Administration. State Operations Manual for Provider Certification, Transmittal #250, Effective April 1, 1992. Health Care Financing Administration, Baltimore
Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. Biological Psychiatry 19: 237–256, 1984
Editorial. Top 200 prescription drugs of 1980. American Druggist 193 (Feb): 49–52, 1981
Editorial. Top 200 prescription drugs of 1990. American Druggist 203 (Feb): 56–68, 1991
Eisendrath SJ, Goldman B, Douglas J, Dimatteo L, Van Dyke C. Meperidine-induced delirium. American Journal of Psychiatry 144: 1062–1065, 1987
Feinberg MF. Polymedicine and the elderly: is it avoidable? Pride Institute Journal of Long Term Home Health Gare 8 (Winter): 15–25, 1989
Feldman MD. The syndrome of anticholinergic intoxication. American Family Physician 34: 113–116, 1986
Fraunfelder FT, Meyer SM. Safe use of ocular drugs in the elderly. Geriatrics 39: 97–102, 1984
Frolkis VV. Aging of the autonomic nervous system. In Birren & Schaie (Eds) Handbook of the psychology of aging, pp. 177–189, Van Nostrand Reinhold Company, New York, 1977
Gent AE, Hellier MD. Comparison of cimetidine and pirenzepine in the healing and maintenance of remission in duodenal ulcer. Digestion 46: 233–238, 1990
Gothoni G, Pentikainen P, Vapaapalo HI, Hackman R, Af-Bjorksten K. Absorption of antibiotic: influence of metoclopramide and atropine on serum levels of pivampicillin and tetracycline. Annals of Clinical Research 4: 228–232, 1972
Gross NJ. Ipratropium bromide. New England Journal of Medicine 319: 486–494, 1988
Gruber-Baldini AL, Schaie KW. The prevalence of chronic diseases from HMO records across age and time. Poster presentation at the Annual Meeting of the Gerontological Society of America, 1991
Jaup BH, Stockbrugger RW, Dotevall G. Comparison of the action of pirenzepine and 1-hyoscyamine on gastric acid secretion and other muscarine effects. Scandinavian Journal of Gastroenterology 15 (Suppl. 66): 89–92, 1980
Jenike MA. Anticholinergic delirium: diagnosis and treatment. In Jenike (Ed.) Handbook of geriatric psychopharmacology, pp. 153–157, PSG Publishing Company, Littleton, 1985
Jenike MA. Psychoactive drugs in the elderly: antidepressants. Geriatrics 43: 43–57, 1988
Johnson AL, Hollister LE, Berger PA. The anticholinergic intoxication syndrome: diagnosis and treatment. Journal of Clinical Psychiatry 42: 313–317, 1981
Katz IR, Curlik S, Lesher EL. Use of antidepressants in the frail elderly: when, why and how? Clinics in Geriatric Medicine 4: 203–222, 1988
Kendrick DC. Why assess the aged? A clinical psychologist’s view. British Journal of Clinical Psychology 21: 47–54, 1982
Kenney RA. The aging process. In Kenney (Ed.) The physiology of aging, pp. 15–25, Year Book Medical Publishers, Chicago, 1989
Koller WC. Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 20: 307–311, 1984
Kuhn E, Honzak R. Psychometric studies of pirenzepine. Scandinavian Journal of Gastroenterology 15 (Suppl. 66): 47–53, 1980
Lamy PP. Prescribing for the elderly, pp. 293–312, PSG Publishing Company, Littleton, 1980
Lamy PP. Nonprescription drugs and the elderly. American Family Physician 39: 175–179, 1989
Lamy PP. Physiological changes due to age. Pharmacodynamic changes of drug action and implications for therapy. Drugs & Aging 1: 385–404, 1991
Lefkowitz RJ, Hoffman BB, Taylor P. Drugs acting at synaptic and neuroeffector junctional sites. In Gilman et al. (Eds) Goodman and Oilman–s the pharmacological basis of therapeutics, 8th ed., pp. 99–101, Pergamon Press, Elmsford, 1990
Levy MH, Catalano RB. Control of common physical symptoms other than pain in patients with terminal disease. Seminars in Oncology 12: 411–430, 1985
Lipowski ZJ. Delirium in the elderly patient. New England Journal of Medicine 320: 578–582, 1989
Lipowski ZJ. Delirium (acute confusional states). Journal of the American Medical Association 258: 1789–1792, 1987
Livingston RL, Zucker DK, Isenberg K, Wetzel RD. Tricycline antidepressants and delirium. Journal of Clinical Psychiatry 44: 173–176, 1983
Lloyd PM. Xerostomia: not a phenomenon of aging. Wisconsin Medical Journal 82: 21–22, 1983
Lozewicz S. Bladder outflow obstruction induced by ipratropium bromide. Postgraduate Medical Journal 65: 260–261, 1989
McEvoy JP, Freter S. The dose-response relationship for memory impairment by anticholinergic drugs. Comprehensive Psychiatry 30: 135–138, 1989
McEvoy JP, McCue M, Spring B, Mohs RC, Lavori PW, et al. Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers. American Journal of Psychiatry 144: 573–577, 1987
Malani JT, Robinson GM, Seneviratne EL. Ipratropium bromide induced angle closure glaucoma. Correspondence. New Zealand Medical Journal 95: 749, 1982
National Disease and Therapeutic Index. A medical profile of the over-65 population, IMS America, Plymouth meeting, Pennsylvania, 1991
OTA Project Staff, Solan G, Behney C, Herdman R, Geldband G, et al. Prescription drugs and elderly Americans: ambulatory use and approaches to coverage for Medicare, US Congress, Office of Technology Assessment, Health Program, Washington,DC, 1987
Ouslander JG, Blaustein J, Conner A, Orzeck S, Yong C. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. Journal of Urology 140: 47–50, 1988
Packe GE, Cayton RM, Mashhoudi N. Nebulised ipratropium bromide and salbutamol causing closed-angle glaucoma. Correspondence. Lancet 2: 691, 1984
Peabody CA, Whiteford HA, Hollister LE. Antidepressants and the elderly. Journal of the American Geriatrics Society 34: 869–874, 1986
Peters NL. Snipping the threat of life: antimuscarinic side effects of medications in the elderly. Archives of Internal Medicine 149: 2414–2420, 1989
Piendergast MD, Nasca TJ. Anticholinergic syndrome with procainamide toxicity. Correspondence. Journal of the American Medical Association 251: 2926–2927, 1984
Reilly PP. Anticholinergic toxicity. Rhode Island Medical Journal 60: 293–296, 1977
Richardson JS, Miller PS, Lemay JS, Jyu CA, Neil SG, et al. Mental dysfunction and the blockade of muscarinic receptors in the brains of the normal elderly. Progress in Neuro-Psychopharmacology and Biological Psychiatry 9: 651–654, 1985
Richelson E. Synaptic pharmacology of antidepressants: an update. McLean Hospital Journal 13: 67–88, 1988
Ridker PM. Health hazards of unusual herbal teas. American Family Physician 39: 153–156, 1989
Sadeh M, Braham J, Modan M. Effects of anticholinergic drugs on memory in Parkinson’s disease. Archives of Neurology 39: 666–667, 1982
Sloan RW. Geriatric drug therapy. Journal of Family Practice 13: 599–609, 1981
Stewart DA, Taylor J, Ghosh S, Macphee GJA, Abdullah I, et al. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. European Journal of Clinical Pharmacology 42: 577–580, 1992
Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Archives of General Psychiatry 44: 418–426, 1987
Swift CG. Prescribing in old age. British Medical Journal 296: 913–915, 1988
Snyder SH, Yamamura HI. Antidepressants and the muscarinic acetylcholine receptor. Archives of General Psychiatry 34: 236–239, 1977
Tashkin DP, Ashutosh K, Bleeker ER, Britt EJ, Cugell DW, et al. Comparison of the anticholinergic bronchodilator ipratrop-ium bromide with metaproterenol in chronic obstructive pulmonary disease. American Journal of Medicine 81 (Suppl. 5A): 81–89, 1986
Tune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Archives of General Psychiatry 37: 293–297, 1980
Van Arsdalen KN, Wein AJ. Drug-induced sexual dysfunction in older men. Geriatrics 39: 63–68, 1984
Wilkinson JA. Side effects of transdermal scopolamine. Journal of Emergency Medicine 5: 389–392, 1987
World Health Organization. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. British Journal of Psychiatry 156: 412, 1990
Ziskind AA. Transdermal scopolamine-induced psychosis. Postgraduate Medicine 84: 73–76, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feinberg, M. The Problems of Anticholinergic Adverse Effects in Older Patients. Drugs & Aging 3, 335–348 (1993). https://doi.org/10.2165/00002512-199303040-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199303040-00004